During 2021, AstraZeneca announced that from September 2021 the Company would stop making dividend payments by way of cheque. Dividends will only be paid by electronic methods.
Removal of cheques has a number of benefits. There is a positive environmental benefit through the reduction in dividend stationary. Shareholders also benefit from increased payment security and faster receipt of funds when payments are made electronically. In addition, the removal of cheque payments reduces administration for both AstraZeneca and shareholders, and also reduces costs.
Shareholders will need to provide a bank mandate to receive their dividend payment directly into a bank or building society account.
Holders of Ordinary Shares should contact Equiniti on +44 371 384 2030 (International), 0371 384 2030 (UK) or through the online enquiry form on the Equiniti website.
ADR holders should contact Deutsche Bank on +1 212 250 9100 (New York), +44 20 7547 6500 (London) or firstname.lastname@example.org.
Holders of shares traded on Stockholm Nasdaq should contact Euroclear on +46 (0) 8 402 9000.